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Checkpoint inhibitorsa b s t r a c t
The abscopal effect describes the ability of locally administered radiotherapy to induce systemic antitu-
mor effects. Although mentioned for the first time in the 1950s, records of abscopal effects, considered to
be immune-mediated, are scarce with radiotherapy alone. However, with the continued development
and use of immunotherapy, reports on the abscopal effect have become increasingly frequent during
the last decade. Here, we report a patient with advanced malignant pleural mesothelioma who had pro-
gressive disease while on the anti-PDL1 inhibitor pembrolizumab and showed an abscopal response after
palliative radiotherapy.
 2020 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
The introduction of immune-checkpoint inhibitors (ICI) has led
to a paradigm shift in the treatment of patients with metastatic
cancer. However, only a minority of patients across tumor types
respond to these therapies [1]. Recently, several phase II studies
investigating programmed death-ligand 1 PD-(L) 1 inhibitors in
malignant pleural mesothelioma (MPM) show overall response
rates (ORR) between 10 and 29% [2] and efforts are underway to
improve therapeutic outcomes by combining immunotherapy with
traditional oncological interventions like chemotherapy,
anti-angiogenic therapy and radiotherapy (RT).
The abscopal effect refers to a rare phenomenon of tumor
regression at a site distant from the primary site of RT. LocalizedRT induces abscopal effects in several types of cancer, including
melanoma, lymphoma, and renal-cell carcinoma [3,4]. The biologic
characteristics underlying this effect are not fully understood, but
in pre-clinical models and in patients, local irradiation can promote
the release of danger-associated molecular patterns leading to the
recruitment of immune cells, thereby inducing a systemic response
to tumor antigens that protect against local disease relapse and
also mediate distant antineoplastic effects [3,4].
We report here a patient with advanced MPMwho had progres-
sive disease while on the anti-PD-L1 inhibitor pembrolizumab and
showed an abscopal response after palliative RT.2. Case report
A 72-year-old male patient with a history of hypertension,
ischemic heart disease, chronic obstructive pulmonary disease,
and an occupational exposure to asbestos was admitted to our
Hospital in April 2015 with dyspnoea class IV (according to the
New York Heart Association – NYHA), cough and weight loss of
5 kgs in 3 months. A chest CT scan was conducted and revealed a
significant pleural effusion, calcified pleural plaques and mediasti-
nal pleural thickening. 18Flourodeoxyglucose positron emission
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fuse heterogeneous, and moderate uptake of the right pleura with
nodular thickening. Thoracoscopic biopsy and talc pleurodesis
were performed. The pathology showed superficial atypical
mesothelial proliferation without infiltrative pattern. In November
2015, a CT scan revealed an increase of the right pleural nodular
thickening, extending next to the trachea and pericardium of the
right auricle with increased uptake on 18FDG PET/CT. Endo-
bronchial ultrasound transbronchial needle aspiration confirmed
atypical cells compatible with MPM. Tumor staging was T3 N2
M0. The patient was treated with carboplatin area under the curve
(AUC) 5, pemetrexed on day 1 (500 mg/m2) every three weeks
(q3W) for 4 cycles and bevacizumab (15 mg/kg) q3W. After 4
cycles, a CT scan showed partial response (PR). He continued three
cycles of maintenance chemotherapy with pemetrexed and beva-
cizumab at the same doses with reported stable disease (SD). Sub-
sequently, he experienced grade 3 oral mucositis and watering
eyes, and grade 2 nephrotoxicity, prompting chemotherapy
discontinuation.
In July 2016, the patient started immunotherapy with pem-
brolizumab 200 mg intravenously (IV) q3W and the follow-up scan
showed an initial SD followed by a PR documented in December
2016.Fig 1. Diagnostic and radiotherapy simulation imaging throughout the disease cours
corresponding to the timeline for treatment and disease status (from panel A to E). Re
indicate unirradiated right pleural lesions. Panel A (top) reflects the pre-RT status of a pro
after RT when the response to the irradiated and unirradiated lesions has begun (SUV
targeted mediastinal mass and partial response of the abscopal right pleural lesion (SUVm
patient in complete remission (SUVmax 2.8). Panel F shows the CT simulation image fo
represent total dose of 30 Gy (red), 20 Gy (orange), 10 Gy (yellow). The 2 Gy isodose li
references to color in this figure legend, the reader is referred to the web version of thi
86In September 2017, after 20 cycles of pembrolizumab, there was
no clinically relevant treatment-related toxicity, but 18FDG PET/CT
showed progressive enlargement and increased uptake of right
pleural and paramediastinal lesions (Fig. 1A). While pursuing pem-
brolizumab, a 2 arcs volumetric modulated arc therapy was used to
deliver 30 Gy in 10 fractions with 10-MV photons to the parame-
diastinal lesion over two weeks to relieve grade 2 dyspnoea. Right
pleural lesions were not included in the RT volume (Fig. 1F).
Three months after RT, the 18FDG PET/CT scan revealed PR in
both irradiated para-mediastinal and unirradiated right pleural
lesions. (Fig. 1B, C). The response of the unirradiated right pleural
lesion suggested a remarkable abscopal effect.
However, further oligometastatic progression of the disease
with retropharyngeal metastasis, was confirmed by histology.
Immunohistochemical expression of PD-L1 evaluated in the
retropharyngeal metastases, was positive in about 10% of tumor
cells (TPS = 10%) and in several inflammatory cells (CPS = 30). Also,
moderate intratumoral infiltration of CD3-positive T lymphocytes,
was observed and CD8-positive cells accounted for about 25% of
the T-cell population (Fig. 2). In April 2018, retropharyngeal metas-
tases were irradiated using the same radiation dose and technique.
In July 2018, while still on pembrolizumab, his paramediastinal
lesion as well as the retropharyngeal mass were in completee. Axial and coronal (maximum intensity projection – MIP) 18FDG PET/CT scans
d arrows indicate the mediastinal lesions that have been irradiated. White arrows
gressive disease on pembrolizumab (SUVmax 7.3). Panel B shows images 3 months
max 6.5) Panel C shows images 6 months after RT with complete response of the
ax 4). Panel D-E shows images 9 months and 24 months after the first RT with the
r radiotherapy planning, and the target volume in the mediastinum. Isodose lines
ne in white is far from the right abscopal pleural lesion. (For interpretation of the
s article.)
Fig 2. Immunohistochemistry analysis of the retropharyngeal metastasis. The retropharyngeal metastasis was composed of cuboidal or polygonal cells with eosinophilic
cytoplasm and monotonous nuclei with visible nucleoli (A). Tumor cells were positive for cytokeratin (B) and PD-L1, which was also observe in some inflammatory cells (C). A
moderate intratumoral infiltration of CD3-positive T lymphocytes was observed and CD8-positive cells (D) represented about 25% of the T-cell population.
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(Fig. 1D). Nevertheless, a retro-crural metastatic lymph node
emerged and was treated with the same radiation dose and tech-
nique in conjunction with pembrolizumab. The follow-up 18FDG
PET/CT, 24 months after RT revealed a significant decline in the
SUVmax (2.8) of the right pleural lesion (Fig. 1E).3. Discussion
Upon relapse to platinum-based chemotherapy, there are no
other treatment options demonstrating improved survival in
MPM. However, gemcitabine and vinorelbine are widely consid-
ered as second line option [2]. There is growing interests in the
use of ICI in the management of MPM. For example, the phase I
expansion cohort of KEYNOTE-028 trial showed a 20% objective
response rate (ORR) and a median progression-free survival (PFS)
of 5.4 months with pembrolizumab [5]. More recently, the phase
III PROMISE-meso trial showed no improved PFS with pem-
brolizumab over chemotherapy in patients with MPM. In this trial,
144 patients with relapsed MPM were randomized 1:1 to receive
200 mg of fixed-dose pembrolizumab IV on day 1 of q3W cycle
(n = 73) or physician’s choice chemotherapy of gemcitabine at
1000 mg/m2 on days 1 and 8 q3W, vinorelbine at 30 mg/m2on days
1 and 8 q3W, or vinorelbine at 60 or 80 mg/m2on days 1 and 8 q3W
(n = 71). PFS was 2.5 months for pembrolizumab compared with
3.4 months for chemotherapy (HR, 1.06; 95% CI, 0.73–1.53;
P = 0.76) [6].
Our patient has been treated in a similar way than in the pem-
brolizumab arm of the PROMISE-meso trial. One year after an ini-
tial PR to pembrolizumab, he progressed in the right mediastinum
and pleura. While continuing with pembrolizumab, palliative RT
was performed to the mediastinum and the patient developed a
systemic abscopal response in unirradiated pleural areas. We87believe that the response observed is an abscopal effect as it was
observed after progression to 20 cycles of pembrolizumab suggest-
ing a systemic immune response triggered by RT. The unirradiated
pleural lesions received less than 0.5 Gy, further supporting that
disease regression at this distant site was due to an enhanced sys-
temic response to localized irradiation. Subsequently, the patient
developed extra-thoracic oligometastatic disease and pem-
brolizumab was continued with interim localized RT. At every turn
of RT, the patient achieved a genuine and durable clinical response.
Five years after diagnosis, the patient remains clinically and radio-
logically stable and received his 70th cycle of pembrolizumab, in
November 2020. As far as we know, this is the first MPM abscopal
effect reported in the literature.
Our clinical observation is consistent with previous reports
demonstrating that mobilization of antitumor immunity is an
important determinant of the overall clinical efficacy of RT in both
targeted and distant tumors [6,8]. Beside its direct tumoricidal
effects, moderate to high-doses of conventional hypofractionated
RT can produce important immunomodulatory effects [3,4],
including the increase exposure of tumor-associated antigen
through in situ vaccination effects, and the tumor microenviron-
ment (TME) reprogramming through the upregulation of cytokines
and chemokines, normalization of the tumor vasculature, and acti-
vation of dendritic cells (DCs). In essence, RT can promote T cell
homing, migration into the tumor, tumor cell recognition, and
effector function [9]. However, several immunosuppressive loops
in the TME may be obstacles for the abscopal effect. Upregulation
of PD-L1-following RT was documented in several preclinical stud-
ies and occurred in the first 24 h following 10 Gy in 5 fractions irra-
diation [10]. Radiation induced-PD-L1 upregulation is mediated via
increased production of IFNc by T cells infiltrating the TME follow-
ing RT, which in turn induces PD-L1 expression on tumor cells.
Therefore, the concomitant administration of RT with anti PD-L1
antibody, as it was performed in our patient, could have overcome
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response. The optimal dose and fractionation may be an important
determinant of the abscopal effect. It has been shown that a single
20 Gy dose of radiation is less effective than a 24 Gy in three frac-
tions or 30 Gy in five fractions regimens administered concomi-
tantly with ICI [11]. Vanpouille-Box et al demonstrated that the
abscopal effect is abrogated with radiation dose per fraction
greater than 18 Gy due to the upregulation of Trex1, an enzyme
that shuttles DNA outside the cell impeding the activation of the
inducible IFN-I pathway, cGAS/STING which is essential for the
activation of antigen presenting cells [12]. We used radiation doses
of 3 Gy delivered in 10 fractions, which has proven to be safe and
other groups have demonstrated abscopal effects using a similar
fractionation [13].
4. Conclusion
Abscopal effect may be observed in MPM treated with concomi-
tant anti-PD-L1 and RT. However, this is a rare observation and
does not justify implementation in routine clinical practice; and
robust hypothesis-testing clinical trials with study of patients’
biopsies are required to determine the appropriate radiation and
immunotherapy approach to be implemented in the clinical set-
ting. It is possible that enhancing innate and adaptive immunity
by combining RT and immunotherapy could induce more abscopal
effects.
Declaration of Competing Interest
The authors declare that they have no known competing finan-
cial interests or personal relationships that could have appeared
to influence the work reported in this paper.
Acknowledgement
Thoracic oncology unit of Lausanne university Hospital. Ludwig
Institute for Cancer Research.88References
[1] Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity
2020;52:17–35.
[2] Scherpereel A, Wallyn F, Albelda SM, Munck C. Novel therapies for malignant
pleural mesothelioma. Lancet Oncol 2018;19:e161–72.
[3] Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities
leveraging immunity for the next oncology practice: radiation-
immunotherapy combinations. CA Cancer J Clin 2017;67:65–85.
[4] Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of
local radiotherapy: using immunotherapy to make a rare event clinically
relevant. Cancer Treat Rev. 2015;41(6):503–10.
[5] Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, et al. Clinical safety
and activity of pembrolizumab in patients with malignant pleural
mesothelioma (KEYNOTE-028): preliminary results from a non-randomised,
open-label, phase 1b trial. Lancet Oncol 2017;18:623–30.
[6] Popat S, Curioni-Fontecedro A, Polydoropoulou V, Shah R, O’Brien M, Pope A,
et al. A multicentre randomized phase III trial comparing pembrolizumab (P)
vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural
mesothelioma (MPM): results from the European Thoracic Oncology Platform
(ETOP 9-15) PROMISE-meso trial. Ann Oncol 2019;30:v851.
[7] Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al.
Immunologic correlates of the abscopal effect in a patient with melanoma. N
Engl J Med 2012;366:925–31.
[8] Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing
radiation inhibition of distant untreated tumors (abscopal effect) is immune
mediated. Int J Radiat Oncol Biol Phys 2004;58:862–70.
[9] Weichselbaum RR, Liang H, Deng L, Fu Y-X. Radiotherapy and immunotherapy:
a beneficial liaison?. Nat Rev Clin Oncol 2017;14:365–79.
[10] Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al.
Acquired resistance to fractionated radiotherapy can be overcome by
concurrent PD-L1 blockade. Cancer Res 2014;74:5458–68.
[11] Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC,
et al. Fractionated but not single-dose radiotherapy induces an immune-
mediated abscopal effect when combined with anti–CTLA-4 antibody. Clin
Cancer Res 2009;15:5379–88.
[12] Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider
RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour
immunogenicity. Nat Commun 2017;8:15618.
[13] Ko EC, Benjamin KT, Formenti SC. Generating antitumor immunity by targeted
radiation therapy: role of dose and fractionation. Adv Radiat Oncol
2018;3:486–93.
